Skip to main content
Erschienen in: Digestive Diseases and Sciences 9/2018

24.05.2018 | Original Article

Tumor Necrosis Factor Ligand-Related Molecule 1A Regulates the Occurrence of Colitis-Associated Colorectal Cancer

verfasst von: Weiwei Niu, Zhe Wu, Jing Wang, Hong Zhang, Wenxiu Jia, Mingyue Yang, Yuxin Luo, Xiaolan Zhang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Tumor necrosis factor ligand-related molecule 1 A (TLlA) is closely related to the occurrence and development of inflammatory bowel disease.

Aims

We aimed to explore whether TLlA was involved in the occurrence of colitis-associated colorectal cancer (CAC).

Methods

Firstly, azoxymethane (AOM) and dextran sulfate sodium (DSS) were used to construct the CAC mice model in wild-type (WT) and TL1A transgenic (Tg) mice with TL1A high expression. The histopathological analysis was used for the evaluation of inflammation level, and the immunohistochemistry staining analysis was used to test the expression and location of proliferating cell nuclear antigen (PCNA) and β-catenin. Secondly, the HCT116 and HT29 cell lines were used for knockdown of TL1A gene for further assay including cell viability, cell clone, cell apoptosis and matrigel invasion. Western blot were used for quantitative protein expression of β-catenin and downstream oncogenes including c-myc and Cyclin D1 after knockdown of TL1A gene.

Results

The evaluation of inflammation level showed that the disease activity index score and tumor formation rate were significantly higher in AOM + DSS/Tg group than that in AOM + DSS/WT group. The expression of PCNA, β-catenin, c-myc, and Cyclin D1 in AOM + DSS/Tg group was significantly higher than that in AOM + DSS/WT group. The cell experiment showed that TL1A knockdown inhibited the cell proliferation, invasion, and migration. Moreover, the expression of c-myc and Cyclin D1 was significantly decreased after TL1A knockdown.

Conclusions

TL1A can induce tumor cell proliferation and promote the occurrence of CAC by activating Wnt/β-catenin pathway.
Literatur
2.
Zurück zum Zitat Lan X, Lan X, Chang Y, et al. Identification of two additional susceptibility loci for inflammatory bowel disease in a Chinese population. Cell Physiol Biochem. 2017;41:2077–2090.CrossRefPubMed Lan X, Lan X, Chang Y, et al. Identification of two additional susceptibility loci for inflammatory bowel disease in a Chinese population. Cell Physiol Biochem. 2017;41:2077–2090.CrossRefPubMed
3.
Zurück zum Zitat Slebioda TJ, Bojarska-Junak A, Stanislawowski M, et al. TL1A as a potential local inducer of IL17A expression in colon mucosa of inflammatory bowel disease patients. Scand J Immunol. 2015;82:352–360.CrossRefPubMed Slebioda TJ, Bojarska-Junak A, Stanislawowski M, et al. TL1A as a potential local inducer of IL17A expression in colon mucosa of inflammatory bowel disease patients. Scand J Immunol. 2015;82:352–360.CrossRefPubMed
4.
Zurück zum Zitat Tremelling M, Berzuini C, Massey D, et al. Contribution of TNFSF15 gene variants to Crohn’s disease susceptibility confirmed in UK population. Inflamm Bowel Dis. 2008;14:733–737.CrossRefPubMed Tremelling M, Berzuini C, Massey D, et al. Contribution of TNFSF15 gene variants to Crohn’s disease susceptibility confirmed in UK population. Inflamm Bowel Dis. 2008;14:733–737.CrossRefPubMed
5.
Zurück zum Zitat Siakavellas SI, Bamias G. Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation. Inflamm Bowel Dis. 2015;21:2441–2452.PubMed Siakavellas SI, Bamias G. Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation. Inflamm Bowel Dis. 2015;21:2441–2452.PubMed
6.
Zurück zum Zitat Yoshihiro A, Minoru N. The role of TL1A and DR3 in autoimmune and inflammatory diseases. Mediators Inflamm. 2013;2013:258164. Yoshihiro A, Minoru N. The role of TL1A and DR3 in autoimmune and inflammatory diseases. Mediators Inflamm. 2013;2013:258164.
7.
Zurück zum Zitat Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008;135:552–567.CrossRefPubMedPubMedCentral Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008;135:552–567.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Zaki MH, Vogel P, Malireddi RK, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell. 2011;20:649–660.CrossRefPubMedPubMedCentral Zaki MH, Vogel P, Malireddi RK, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell. 2011;20:649–660.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10:353–358.CrossRefPubMed Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 2009;10:353–358.CrossRefPubMed
10.
Zurück zum Zitat Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012;3:107.CrossRefPubMedPubMedCentral Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012;3:107.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.CrossRefPubMed Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.CrossRefPubMed
12.
Zurück zum Zitat Gemoll T, Kollbeck SL, Karstens KF, et al. EB1 protein alteration characterizes sporadic but not ulcerative colitis associated colorectal cancer. Oncotarget.. 2017;8:54939–54950.CrossRefPubMedPubMedCentral Gemoll T, Kollbeck SL, Karstens KF, et al. EB1 protein alteration characterizes sporadic but not ulcerative colitis associated colorectal cancer. Oncotarget.. 2017;8:54939–54950.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Pikoulis E, Margonis GA, Angelou A, et al. Statins in the chemoprevention of colorectal cancer in established animal models of sporadic and colitis-associated cancer. Eur J Cancer Prev. 2016;25:102–108.CrossRefPubMed Pikoulis E, Margonis GA, Angelou A, et al. Statins in the chemoprevention of colorectal cancer in established animal models of sporadic and colitis-associated cancer. Eur J Cancer Prev. 2016;25:102–108.CrossRefPubMed
14.
Zurück zum Zitat Yaeger R, Shah MA, Miller VA, et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151(278.e276):287.e276. Yaeger R, Shah MA, Miller VA, et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151(278.e276):287.e276.
15.
Zurück zum Zitat Lu T, Dang S, Zhu R, et al. Adamts18 deficiency promotes colon carcinogenesis by enhancing β-catenin and p38MAPK/ERK1/2 signaling in the mouse model of AOM/DSS-induced colitis-associated colorectal cancer. Oncotarget. 2017;8:18979–18990.PubMedPubMedCentral Lu T, Dang S, Zhu R, et al. Adamts18 deficiency promotes colon carcinogenesis by enhancing β-catenin and p38MAPK/ERK1/2 signaling in the mouse model of AOM/DSS-induced colitis-associated colorectal cancer. Oncotarget. 2017;8:18979–18990.PubMedPubMedCentral
16.
Zurück zum Zitat Shih DQ, Barrett R, Zhang X, et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS ONE. 2011;6:e16090.CrossRefPubMedPubMedCentral Shih DQ, Barrett R, Zhang X, et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS ONE. 2011;6:e16090.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sethi G, Sung B, Aggarwal BB. Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv Exp Med Biol. 2009;647:207–215.CrossRefPubMed Sethi G, Sung B, Aggarwal BB. Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv Exp Med Biol. 2009;647:207–215.CrossRefPubMed
18.
Zurück zum Zitat Wang X, Mandal AK, Saito H, et al. Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/beta-catenin signaling pathway. Toxicol Appl Pharmacol. 2012;262:11–21.CrossRefPubMedPubMedCentral Wang X, Mandal AK, Saito H, et al. Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/beta-catenin signaling pathway. Toxicol Appl Pharmacol. 2012;262:11–21.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lee G, Goretsky T, Managlia E, et al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology. 2010;139(869.e9):881.e9. Lee G, Goretsky T, Managlia E, et al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology. 2010;139(869.e9):881.e9.
20.
Zurück zum Zitat Claessen MMH, Schipper MEI, Bas O, Siersema PD, Offerhaus GJA, Vleggaar FP. WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell Oncol. 2010;32:303–310.PubMedPubMedCentral Claessen MMH, Schipper MEI, Bas O, Siersema PD, Offerhaus GJA, Vleggaar FP. WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell Oncol. 2010;32:303–310.PubMedPubMedCentral
21.
Zurück zum Zitat Brown JB, Lee G, Managlia E, et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 2010;138:595.CrossRefPubMed Brown JB, Lee G, Managlia E, et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 2010;138:595.CrossRefPubMed
Metadaten
Titel
Tumor Necrosis Factor Ligand-Related Molecule 1A Regulates the Occurrence of Colitis-Associated Colorectal Cancer
verfasst von
Weiwei Niu
Zhe Wu
Jing Wang
Hong Zhang
Wenxiu Jia
Mingyue Yang
Yuxin Luo
Xiaolan Zhang
Publikationsdatum
24.05.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5126-0

Weitere Artikel der Ausgabe 9/2018

Digestive Diseases and Sciences 9/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.